Japan Genome Editing Market Size & Outlook, 2023-2030
Japan genome editing market, 2018-2030 (US$M)
Related Markets
Japan genome editing market highlights
- The Japan genome editing market generated a revenue of USD 229.6 million in 2023 and is expected to reach USD 768.0 million by 2030.
- The Japan market is expected to grow at a CAGR of 18.8% from 2024 to 2030.
- In terms of segment, (crispr)/cas9 was the largest revenue generating technology in 2023.
- (CRISPR)/Cas9 is the most lucrative technology segment registering the fastest growth during the forecast period.
Genome editing market data book summary
| Market revenue in 2023 | USD 229.6 million |
| Market revenue in 2030 | USD 768.0 million |
| Growth rate | 18.8% (CAGR from 2023 to 2030) |
| Largest segment | (crispr)/cas9 |
| Fastest growing segment | (CRISPR)/Cas9 |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease |
| Key market players worldwide | Merck KGaA, Cibus Inc Ordinary Shares - Class A, Recombinetics, Sangamo Therapeutics Inc, Editas Medicine Inc, Precision BioSciences Inc, CRISPR Therapeutics AG, Intellia Therapeutics Inc, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, AstraZeneca PLC, Takara Bio Inc, Horizon Discovery, Danaher Corp, Genscript Biotech Corp Class H, New England Biolabs, Origene Technologies, Bluebird bio Inc, Lonza Group Ltd, Thermo Fisher Scientific Inc |
Other key industry trends
- In terms of revenue, Japan accounted for 2.9% of the global genome editing market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China genome editing market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 626.7 million by 2030.
(crispr)/cas9 was the largest segment with a revenue share of 43.51% in 2023. Horizon Databook has segmented the Japan genome editing market based on (crispr)/cas9, talens/megatals, zfn, meganuclease covering the revenue growth of each sub-segment from 2018 to 2030.
An increasing number of Japanese companies are acquiring licenses to the CRISPR-Cas9 technology, potentially driving market growth. For instance, in July 2021, ERS Genomics declared a license agreement with Nippon Gene to grant Nippon gene access to ERS Genomics’ CRISPR/Cas9 genome editing portfolio.
Efforts undertaken by government agencies to boost development of genetically modified food products are anticipated to accelerate utilization of genome editing technology in product development methods. For instance, in December 2019, the Consumer Affairs Agency (CAA) declared that foods made using genome editing techniques are not required to undergo safety inspections.
In addition, increasing prevalence of genetic diseases and diabetics coupled with growing genomic research initiatives is expected to drive the market in Japan. In Japan, around 13.5% of the total population either has type 2 diabetes or impaired glucose tolerance. More than 12 million Japanese people suffer from hyperglycemia.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Genome Editing Market Scope
Genome Editing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan genome editing market size, by technology, 2018-2030 (US$M)
Japan Genome Editing Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
